Researchers from Stellenbosch University's Faculty of Medicine and Health Sciences reported on a groundbreaking clinical research at the Union Conference on Lung Health meeting in Paris revealing that an oral antibiotic taken once daily for six months significantly lowered the likelihood of developing drug-resistant tuberculosis. The study showed that the risk for multidrug-resistant tuberculosis infection in children was reduced by 56% with levofloxacin. TB remains as one of the top causes of death in children globally and is one of the top killers of children below 5 years of age. 

Guest: Professor Anneke Hesseling-  Director of the Desmond Tutu TB Centre and the overall Principal Investigator of the TB-CHAMP trial, at Stellenbosch University